GSK3B and esophageal squamous cell carcinoma: Additionally, Li et al. (2020a) reported that MEG3 inhibited EMT in ESCC by inhibiting the phosphoserine aminotransferase 1 (PSAT-1)-dependent glycogen synthase kinase 3 beta (GSK-3β)/Snail signaling pathway.